Piper Sandler analyst Christopher Raymond downgrades AlloVir (NASDAQ:ALVR) from Overweight to Neutral and lowers the price target from $27 to $1.5.
Piper Sandler Downgrades AlloVir to Neutral, Lowers Price Target to $1.5
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.